Group 1 - Jiangsu Chuangjian Medical Technology Co., Ltd. (Chuangjian Medical) has officially announced the termination of its listing on the National Equities Exchange and Quotations (NEEQ) after just 271 days, marking a rapid exit from the capital market [1][2] - The company initiated its listing process in early 2024, signed a contract with CITIC Securities, and officially listed on NEEQ on November 11, 2024, becoming the third collagen-restructured enterprise to do so [2] - The decision to withdraw may stem from a strategic shift, allowing the company to avoid the disclosure pressures and compliance costs associated with being a public company during a critical period of technological breakthroughs in collagen [2][3] Group 2 - Prior to its delisting, Chuangjian Medical received two core patent authorizations related to collagen technology, indicating a strong focus on innovation and potential market applications in the medical beauty sector [2] - The company has formed a strategic partnership with a leading global cosmetics OEM, Kosei Meishi, to develop new regenerative medical materials, suggesting a pivot towards business-to-business (B2B) opportunities [2][3] - The broader trend of medical companies exiting the NEEQ highlights a common challenge in the industry, where compliance costs and liquidity issues are increasingly burdensome, leading to a significant rise in delistings [3][4] Group 3 - The exit of Chuangjian Medical is part of a larger trend, with a 40% year-on-year increase in delistings among biomedicine companies on NEEQ in the first half of 2025, indicating a significant capital withdrawal from the sector [4] - The company’s strategy emphasizes enhancing product innovation and leveraging technological advancements to attract strategic investments, potentially positioning itself for future growth in higher-tier capital markets [4]

Core Viewpoint - The news highlights the rise of Fan Daidi, the new vice president of Northwest University, as a prominent figure in the business world, particularly in the biotechnology sector, due to her significant stake in the listed company, Juzhi Biotechnology, which has achieved substantial market value and success in the industry [1][4]. Company Overview - Juzhi Biotechnology, co-founded by Fan Daidi and her husband Yan Jianya in 2001, has successfully commercialized human-like collagen through genetic engineering, becoming a model for industry-academia collaboration [3]. - As of 2017, Juzhi Biotechnology had established 11 production lines, with its products being used in over 1,000 hospitals across seven countries and regions, achieving cumulative terminal sales of nearly 10 billion yuan [3]. Market Performance - Juzhi Biotechnology went public on the Hong Kong Stock Exchange in November 2022, with Fan Daidi listed as a co-founder and chief scientific officer [3]. - As of May 12, 2023, Juzhi Biotechnology's market capitalization was approximately 836 billion HKD (about 773 billion yuan), contributing significantly to the combined market value of nearly 900 billion yuan for both Juzhi Biotechnology and another listed company, Xi'an Triangle Defense [4]. Leadership and Governance - Fan Daidi was appointed as the vice president of Northwest University on April 1, 2025, after serving in various leadership roles within the university [4]. - The appointment of Fan Daidi complies with the management regulations for leadership personnel in public institutions in Shaanxi Province, confirming her eligibility for the role [4].

Core Insights - The news highlights the controversy surrounding Fan Daidi, the vice president of Northwest University, who became the richest person in Shaanxi through her role as a co-founder of the Hong Kong-listed company, Giant Bio (2367.HK), which has a market value of HKD 90.5 billion as of May 15 [2] - The intersection of academic authority and capital interests raises questions about the ability of university leaders to balance public responsibilities with private wealth, exposing deep-seated contradictions in the field of industry-academia-research transformation [2][10] Company Performance - Giant Bio's revenue reached CNY 5.538 billion in 2024, a year-on-year increase of 57.2%, with a net profit of CNY 2.061 billion, up 42.4%, and a gross margin of 82.1% [4] - The brand "Kefumei" generated CNY 4.542 billion in revenue, contributing 87.04% to the total revenue growth of Giant Bio, with its revenue soaring from CNY 289 million in 2019 to CNY 2.788 billion in 2023 [4] - The Chinese recombinant collagen market is projected to grow from CNY 18.5 billion in 2022 to CNY 108.3 billion by 2027, with Giant Bio leading this growth through its flagship brand [4] Competitive Advantages - Giant Bio's competitive edge lies in its proprietary library of over 40 types of collagen and its strong synthetic biology platform, making it difficult for competitors to replicate [5] - The company has established industry standards and transparency commitments, which help marginalize weaker competitors and solidify its market position [5][6] Policy and Regulatory Context - The case of Fan Daidi illustrates the interplay between policy design and business acumen, as her career trajectory aligns with the loosening of technology transfer policies in China [5][10] - Giant Bio benefits from a favorable tax rate of 15% and a closed-loop system that converts public research resources into private competitive advantages [6] Ethical Considerations - The blending of public resources and private interests raises concerns about the privatization of public value, particularly given that 63% of Giant Bio's R&D team comes from Northwest University [9][11] - The complex ownership structures employed by Fan Daidi to maintain her business interests while serving as a university administrator challenge the expectations of academic neutrality [11][12]

Core Insights - The article highlights the achievements of Fan Daidi, a prominent figure in the biotechnology sector, who has transitioned from academia to becoming a billionaire entrepreneur through her innovations in collagen production [1][10]. Group 1: Background and Education - Fan Daidi was born into a rural family in Shaanxi and aspired to be a doctor but shifted to chemical engineering due to vision issues [5]. - She became the first female PhD in China's bio-chemical engineering field and returned to Northwest University to start her research career with limited funding [5][6]. Group 2: Innovations and Business Development - In 2000, she successfully produced human-like collagen using genetic engineering, leading to the first patent in this area in China [7]. - This innovation addressed issues related to animal-derived collagen, such as viral risks and immune rejection, and laid the foundation for her company, Juzi Biotechnology [7][8]. Group 3: Company Performance - Juzi Biotechnology achieved over 10 billion yuan in cumulative sales by 2022, establishing itself as a leader in the collagen market [8]. - The company's revenue surged from 900 million yuan in 2019 to 5.5 billion yuan in 2024, with net profits increasing from 550 million yuan to 2.06 billion yuan during the same period [14]. Group 4: Personal and Professional Identity - Fan Daidi holds significant stakes in Juzi Biotechnology and another company, Triangle Defense, with a combined market value of approximately 443 billion yuan [10][13]. - Despite her wealth, she continues to serve as a strict mentor at Northwest University, balancing her roles as an academic leader and a successful entrepreneur [16][17].